Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1717

1.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials..

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review.

PMID:
18477802
2.

Choosing the best endpoint.

Christensen E.

J Hepatol. 2008 Oct;49(4):672-3. doi: 10.1016/j.jhep.2008.07.012. Epub 2008 Jul 30.

PMID:
18718690
3.

Re: Design and endpoints of clinical trials in hepatocellular carcinoma.

Di Maio M, Daniele B, Gallo C, Perrone F.

J Natl Cancer Inst. 2008 Nov 5;100(21):1557; author reply 1557-8. doi: 10.1093/jnci/djn341. Epub 2008 Oct 28. No abstract available.

PMID:
18957679
4.

Updated treatment approach to hepatocellular carcinoma.

Llovet JM.

J Gastroenterol. 2005 Mar;40(3):225-35. Review.

PMID:
15830281
5.

Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?

Lencioni R, Chen XP, Dagher L, Venook AP.

Oncologist. 2010;15 Suppl 4:42-52. doi: 10.1634/theoncologist.2010-S4-42. Review.

6.

Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

Rimassa L, Santoro A.

Expert Rev Anticancer Ther. 2009 Jun;9(6):739-45. doi: 10.1586/era.09.41.

PMID:
19496710
7.

[Hepatocellular carcinoma].

Kondo S, Ueno H, Morizane C, Okusaka T.

Gan To Kagaku Ryoho. 2010 Jul;37(7):1219-23. Japanese.

PMID:
20647702
8.

Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients.

Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D'Onofrio M, Guglielmi A.

J Gastrointest Surg. 2009 Jul;13(7):1313-20. doi: 10.1007/s11605-009-0903-x. Epub 2009 May 6.

PMID:
19418103
9.

Clinical trial design in hepatocellular carcinoma.

Johnson PJ, Billingham LJ.

Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):119-27. Review.

PMID:
15757808
10.

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Lencioni R, Llovet JM.

Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. Review.

PMID:
20175033
11.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A.

Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Review.

PMID:
19228077
12.

Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.

Lefebvre JL, Ang KK; Larynx Preservation Consensus Panel..

Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1293-303. doi: 10.1016/j.ijrobp.2008.10.047.

PMID:
19306746
13.
14.
15.

Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer.

Treiber G, Wex T, Malfertheiner P.

J Cancer Res Clin Oncol. 2009 Feb;135(2):271-81. doi: 10.1007/s00432-008-0443-x. Epub 2008 Jul 19.

PMID:
18642029
16.

Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.

Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M.

Hepatology. 2006 Oct;44(4):891-5.

PMID:
17006925
17.

Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.

Packianathan S, Mehta RG, Mehta RR, Hall WH, Boerner PS, Beckett LA, Vijayakumar S.

Cancer J. 2004 Nov-Dec;10(6):357-67.

PMID:
15701267
18.

A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma.

Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ.

J Cancer Res Clin Oncol. 2009 Oct;135(10):1437-45. doi: 10.1007/s00432-009-0588-2. Epub 2009 May 1.

PMID:
19408012
19.

Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.

Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H.

Anticancer Drugs. 2010 Mar;21(3):326-32. doi: 10.1097/CAD.0b013e3283350e26.

PMID:
20016366
20.

[Controlled randomized clinical trials].

Jaillon P.

Bull Acad Natl Med. 2007 Apr-May;191(4-5):739-56; discussion 756-8. French.

PMID:
18225427

Supplemental Content

Support Center